
    
      This is a randomized controlled trial to evaluate the efficacy of ivermectin in COVID-19
      outpatients reducing the risk of progression to severe disease.

      Patients with COVID-19 infection are randomized to receive a single dose of 200mcg/kg of
      ivermectin or a placebo.

      The randomization code is generated by the trial statistician. The allocation is made after
      fulfilment of both inclusion and exclusion criteria.
    
  